Talis Biomedical Corporation

OTCPK:TLIS Stock Report

Market Cap: US$3.1m

Talis Biomedical Past Earnings Performance

Past criteria checks 0/6

Talis Biomedical has been growing earnings at an average annual rate of 2%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 76% per year.

Key information

2.0%

Earnings growth rate

8.1%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate-76.0%
Return on equity-104.9%
Net Margin-12,506.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Aug 16
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Talis Biomedical reports Q2 results

Aug 02

Talis Biomedical Aims For Manufacturing Turnaround

Mar 17

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Feb 08
Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18
News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14
Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Revenue & Expenses Breakdown

How Talis Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:TLIS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-51260
31 Mar 241-57260
31 Dec 232-62250
30 Sep 232-75260
30 Jun 233-86290
31 Mar 233-98320
31 Dec 225-113370
30 Sep 225-115420
30 Jun 225-127460
31 Mar 224-165470
31 Dec 218-192420
30 Sep 218-208350
30 Jun 2117-199260
31 Mar 2118-144180
31 Dec 2011-91130
30 Sep 2012-1100
31 Dec 1942670
31 Dec 182-2150

Quality Earnings: TLIS is currently unprofitable.

Growing Profit Margin: TLIS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TLIS is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare TLIS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLIS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: TLIS has a negative Return on Equity (-104.94%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 16:23
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Talis Biomedical Corporation is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Derik de BruinBofA Global Research
Mark MassaroBTIG
Tycho PetersonJ.P. Morgan